Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CTSC | P53634 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064893 | 0.89 | PREP (0.44) | PREPHTRA1P2RX7CTSCMAPK1 | |
| SCHEMBL15064894 | 0.89 | PREP (0.44) | PREPHTRA1P2RX7CTSCMAPK1 | |
| SCHEMBL15081660 | 0.89 | PREP (0.44) | PREPHTRA1P2RX7CTSKMAPK1 | |
| SCHEMBL14822178 | 0.87 | PREP (0.41) | PREPHTRA1MAPK1CHRM2CHRM1 | |
| SCHEMBL15081643 | 0.86 | CTSC (0.46) | GPR119CTSKCTSC | |
| SCHEMBL16622346 | 0.86 | PREP (0.40) | PREPHTRA1CTSCMAPK1CHRM2 | |
| SCHEMBL15081676 | 0.85 | HTRA1 (0.44) | PREPHTRA1CTSCMAPK1CHRM2 | |
| SCHEMBL14822155 | 0.84 | GPR119 (0.44) | PREPHTRA1GPR119CTSC | |
| SCHEMBL15081645 | 0.84 | PREP (0.40) | PREPHTRA1CTSCMAPK1CHRM2 | |
| SCHEMBL15081677 | 0.84 | ALDH1A1 (0.42) | PREPHTRA1GPR119CTSCMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999975-B2 | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-20130172327-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172327-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | CTSS, CTSB, CTSG | PREP 37/4885HTRA1 577/4885GPR119 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.